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inTroducTion
This report presents a summary of findings from a review of 
evidence published in peer-reviewed journals between 2004 and 
2007 on the contribution of community pharmacy to improving the 
public’s health. This current review adds to the evidence identified 
from our two previous reviews covering the periods 1990-20011 and 
2001-20042. It was commissioned by the Department of Health. 
This Management Summary focuses on evidence of effectiveness, 
quality, costs/cost-effectiveness and skill mix where available. Key 
findings relating to pharmacists’ attitudes and practice are also 
summarised. 
meThods
A systematic search of international peer-reviewed literature was 
undertaken using the same search terms as the previous two reviews 
of this subject. Data were extracted using the same structured matrix 
as in the previous reviews, with a sample of reviews cross-checked 
to assure accuracy. In total 96 papers were reviewed: 21 smoking 
cessation; 13 emergency hormonal contraception; 12 diabetes; 16 
coronary heart disease prevention and management (including 8 
lipid management); 8 substance misuse; 8 osteoporosis screening/
prevention; 6 weight management; 3 hypertension; 3 sexually 
transmitted infections; 3 immunisation; 2 contraception; 1 HIV 
awareness. Most studies were conducted in Canada, Australia and 
the US. 
resulTs
smoking cessaTion
21 papers were reviewed, covering 18 studies. 
overview: 
n  New evidence from a large study showing similar abstinence 
rates from one-to-one treatment services provided by community 
pharmacists and primary care nurses, but rates were lower than 
for group interventions with specialist advisors. 
n  Quality criteria developed in 2 studies could be used to further 
develop frameworks for UK services.
n  Some evidence that involving pharmacy support staff increases 
the provision of brief advice and recording of smoking status in 
patient medication records.
n  Further evidence that pharmacists remain apprehensive about 
proactively raising smoking with their customers.
effecTiveness
There were 6 intervention studies, 2 of which were conducted in 
the UK. A large London study using a quasi experimental design 
with 1500 participants and validated abstinence found similar 
abstinence rates at four weeks (19%) for people receiving the 
service on a one-to-one basis from community pharmacists and 
primary care nurses, compared with 30% for those receiving a 
group treatment service from ‘behaviour change experts’ (McEwen 
et al 2006).  The authors commented that the difference may be 
due to the additional behavioural support given by the latter.  Self 
reported abstinence rates were 45% (four weeks), 35% (12 weeks) 
and 15.8% at 44 weeks in an uncontrolled, non-validated Scottish 
study with 177 clients in 18 pharmacies.
A US study tested the feasibility of a protocol to target specific people 
for questioning and ‘brief interventions’ [akin to ‘brief advice’ in 
the UK] about smoking in two community pharmacies (Purcell et al 
2006). The smoking status of 57% and 29% of eligible people was 
recorded in the two pharmacies.
QualiTy
Quality criteria were developed and applied in studies in the UK 
(Scotland) and Norway. 
A quality criteria assessment framework developed in a Scottish 
study included 13 elements: cessation rates of 30% (one month); 
28% (three months); 14.3% (one year); and in those not abstaining, 
to achieve a reduction in smoking levels; improve access to smoking 
cessation services; client group from areas of inequality; client 
satisfied with the service; successful use of the ‘stage of change’ 
model; ensure ongoing written material is available; subjective 
estimate of reduced workload in general practice; avoid increasing 
time pressure on pharmacists; pharmacists satisfied with service; 
achieve a cost of £300 per quitter] (Cramp et al 2007). 6 of the 
13 criteria were achieved: improved access; clients satisfied with 
service; successful use of ‘stages of change’ model; one month 
30% success rate; 3 month 28% success rate; and, in those not 
abstaining, achieve a reduction in smoking levels.
A quality framework for advice during sales of over the counter 
nicotine replacement therapy (NRT) developed in Norway had 
12 criteria (6 relating to customer service and 6 on content of 
pharmaceutical advice) (Granas et al 2004). A mystery shopper 
study found a mean score of 17.3 (of a possible 45) on a first visit 
and 16.2 on the second visit.
1Anderson, C, Blenkinsopp, A, and Armstrong, M. The contribution of community pharmacy to improving the public’s health: Evidence from the peer-reviewed literature of 1990-2001. PharmacyHealthLink and 
Royal Pharmaceutical Society of Great Britain, 2003.  
http://www.pharmacyhealthlink.org.uk/ (accessed 16/3/08).
2C Anderson, Blenkinsopp A, Armstrong M. The contribution of community pharmacy to improving the public’s health. Evidence from the peer reviewed literature 2001-2004. Pharmacy HealthLink 
and Royal Pharmaceutical Society of Great Britain, 2005. http://www.pharmacyhealthlink.org.uk/ (accessed 16/3/08).
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cosTs and cosT effecTiveness
The cost per quitter was £525 in a Scottish study, compared with the 
quality criterion of £300 in that programme (Cramp et al 2007).
skill mix
In a US study the pharmacy which involved its dispensing technicians 
in implementing a protocol for offering brief interventions [brief 
advice in the UK] and recording smoking status had recording rates 
and numbers of interventions roughly double those in the pharmacy 
that did not use technicians (Purcell et al 2006).
 
aTTiTudes and pracTice
Two studies from Canada and Australia explored pharmacists’ 
attitudes (Brewster et al 2005; Edward et al 2006) and one US 
study (Purcell et al 2006) investigated actual practice in relation to 
unsolicited questioning and advice about smoking. Most pharmacists 
did not routinely ask about or record the smoking status of their 
customers. Pharmacists in the Canadian and Australian studies 
were apprehensive about raising the topic of smoking cessation 
and expressed some concerns about alienating their customers 
(Brewster et al 2005; Edwards et al 2006). 
 
coronary hearT disease 
prevenTion and managemenT
16 papers were reviewed, involving 13 studies. 
overview
n  Further evidence of effectiveness of pharmacy services in 
reducing lipid levels and that the effect was sustained one year 
after the intervention ended.
n  Evidence from a RCT of effectiveness of a pharmacy service in 
significantly increasing prescribing of antiplatelet medicines, 
lipid-lowering treatment, and smoking cessation treatments.
n  A workplace based cardiovascular risk reduction programme 
provided by community pharmacists significantly reduced blood 
pressure and improved lipid profiles but had no effect on weight.
n  A community pharmacy based service where peer health educators 
measured blood pressure and completed cardiovascular risk 
profiles for people with hypertension was well received by 
patients and GPs.
effecTiveness
There were 2 intervention trials. The Canadian Pharmacist 
Intervention in Risk Reduction (PIRR) trial used a ‘before-after’ 
design. 41 pharmacies recruited 217 patients. The primary outcome 
was the proportion of patients with changes in targeted medication. 
There was a significant increase in the prescribing of antiplatelet 
and lipid lowering treatments and of smoking cessation treatments. 
This trial was ended early due to under-recruitment.
The Canadian SCRIP Plus trial was a ‘before and after’ study of 
the effects of pharmacist intervention in lipid management. 42 
pharmacies recruited 419 patients to the study. The mean reduction 
in LDL level was 0.5mmol/L from a baseline mean of 3.5mmol/L, 
representing a 13.4% reduction in relative risk, and 27% of patients 
reached their target LDL level. One year after completion of SCRIP 
Plus patients were followed up and their LDL cholesterol measured. 
The mean LDL level was not significantly different from that one year 
earlier. Most patients still had not reached their target LDL level. 
A workplace-based cardiovascular risk reduction programme 
provided by community pharmacists led to significant reductions 
in systolic and diastolic BP and in LDL but had no significant 
effect on weight (John et al 2006). 56 workers with risk factors for 
cardiovascular disease took part, of mean age 41 years, 37 had 
diabetes mellitus and 19 did not. The number of pharmacist visits 
per participant ranged from 1 to 13, with a mean value of 7. 
In the Cardiovascular Health Awareness Program (CHAP) in Canada, 
people aged over 65 with hypertension were invited by their doctor 
to attend a session in their local pharmacy with a trained volunteer 
peer health educator (PHE). The PHE measured their blood pressure 
and completed a cardiovascular risk profile. A copy of the findings 
was given to the pharmacist and faxed to the doctor. Feedback from 
doctors, PHEs and pharmacists was positive and the pharmacists 
reported increased patient traffic and more dialogue with patients. 
A RCT of CHAP was recently completed and the findings are due to 
be published in 2008.
QualiTy / cosTs / cosT-effecTiveness / skill 
mix
No evidence was found.
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diabeTes
11 studies were reviewed including 2 intervention trials and 2 
reviews.
overview
n  Further evidence of effectiveness of diabetes management 
services provided from pharmacies, leading to a significantly 
greater reduction of approximately 1% in HbA1c compared with 
0.3% in controls.
n  Evidence from a RCT that pharmacy based targeting of people 
with risk factors for diabetes together with ‘point of care’ blood 
glucose testing prior to referral was more effective and more cost 
effective than targeting and referral alone.
n  A diabetes screening and cardiovascular risk assessment service 
resulted in new diagnoses for 16% of those referred and therapy 
changes in 42%.
effecTiveness
A structured review covering 7 experimental studies in the period up 
to 2005 concluded that there was ‘limited evidence of effectiveness 
of community pharmacy based diabetes services’. 
Since the time of that review a substantial amount of further 
evidence has been published. A systematic review (Machado et al 
2007a) with meta-analysis of data from 2247 patients in 16 studies 
found a significant reduction in HbA1c levels in the pharmacists’ 
intervention group (1.00 ± 0.28%; p < 0.001) but not in controls 
(0.28 ± 0.29%; p = 0.335). 
Subsequent to the latter review an Australian study was published 
which tested the effectiveness of a community pharmacy based 
diabetes service in controlled trials (Krass et al 2007a). The numbers 
of patients receiving the intervention were 149 at 28 pharmacies. 
The trial showed statistically and clinically significant reductions in 
HbA1c of 0.97% (compared with 0.27% in controls). 
Pharmacy based screening for undiagnosed diabetes was the subject 
of three studies, conducted in Australia, the US and Switzerland. The 
US study included diabetes testing together with CHD risk assessment 
(Snella et al 2006). The Australian and US studies used simple risk 
factor assessment as a filter prior to diabetes screening and involved 
testing of 1286 and 888 people respectively (Krass et al 2007b ;Snella 
et al 2006). The Swiss paper reported findings from a national screening 
campaign in which 93,258 people were tested (Hersberger et al 2006). 
Follow up to identify subsequent diagnoses was conducted only in the 
Australian study, where 1.7% of those tested were diagnosed as having 
diabetes.  In the US study 81% of those screened were referred, 15% of 
whom had blood glucose measurements outside the defined range. In 
the Swiss campaign 6.9% of those tested were categorised as ‘possible 
diabetes’.
cosTs and cosT effecTiveness
A cost-effectiveness analysis was conducted for 99 patients who 
had received the pharmacy based diabetes service in the earlier 
of the two Australian trials (Taylor et al 2005). Pharmacists were 
paid 40 Australian dollars per hour (approx £18). The mean cost of 
the intervention over nine months was 383 Australian dollars per 
patient (approx £175).
The cost-effectiveness of pharmacy based risk assessment plus 
blood glucose testing (‘sequential screening’, SS) in generating 
a diagnosis of diabetes was compared with pharmacy based risk 
assessment with referral to the GP for blood glucose testing in an 
Australian study (Krass et al 2007b). The rates of diagnosis were 
1.7% and 0.2% respectively. The SS method resulted in fewer 
referrals to the GP and a higher uptake of referrals and was more 
cost-effective.
QualiTy / skill mix
No evidence was found.
hyperTension
Two intervention studies and one systematic review were included. 
The systematic review included 13 trials and found evidence of 
effectiveness of pharmacist input in significantly reducing systolic 
blood pressure (Machado et al 2007b).
overview
n  A systematic review with meta analysis of 13 RCTs covering 
2246 patients found significant reductions in systolic but not 
diastolic BP.
QualiTy / clinical/cosT-effecTiveness / 
skill mix
No evidence was found.
weighT managemenT
Six studies were identified and reviewed
overview
n  Two of  three intervention studies showed a positive effect while 
the third showed no significant change in weight.
Six studies were identified and reviewed whose focus was 
specifically on weight management; 3 involved interventions. In 2 
of these, the service was provided for a total of 316 people and in 
the third, which was an extension of a national health promotion 
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campaign, it was provided for 1370. A service provided in a single 
pharmacy in the US resulted in a mean weight loss of 3.6kg among 
216 people over a mean duration of 26 weeks (Lloyd et al 2007). 
1 in 3 people were able to decrease their BMI category and 1 in 4 
decreased their CHD risk status and BP in those with uncontrolled 
hypertension at baseline was more likely to be controlled. The service 
involved an initial consultation with the pharmacist (scheduled for 
1.5 hours) followed by 15 minute fortnightly follow ups until target 
weight was reached and then a three monthly follow up. The service 
was provided free during the study period and is now offered on a fee-
paying basis. In a Swiss study 3800 people who had participated in 
their community pharmacy-based diabetes screening in Switzerland 
to take part in a programme of lifestyle counselling. Of the 1370 who 
took part, the mean weight lost was 0.6–1.9 kg at 3 months. People 
in the high-risk counselling group (245) showed weight loss of 2.25% 
at 3 months and 2.74% at 1 year (Botomino et al 2007). In addition 
to the specific studies on weight management, weight reduction was 
one of several outcome measures in a workplace health-improvement 
programme where community pharmacists provided education about 
cardiovascular disease, identification of drug therapy problems, and the 
importance of routine blood
pressure, pulse, and weight measurements (John et al 2006). No 
significant effect on weight was found.
emergency hormonal conTracepTion (ehc) 
/ conTracepTion
Thirteen studies were included, one of which was a structured 
review.  
Community pharmacy supply of EHC enables most women to receive 
it within 24 hours of unprotected sexual intercourse . Making EHC 
available OTC did not change the level of use but did change where 
women obtained it, with more women using pharmacies as the 
source (Marston et al 2005). A large US trial of advance availability 
of EHC found no increase in risky sexual behaviour and no significant 
reduction in the number of pregnancies (Rocca et al 2007). No 
differences were observed in use of regular contraception or in risky 
sexual behaviour (Raine et al 2005). Adolescents aged younger than 
16 years behaved no differently in response to increased access to 
EHC from the other age groups (Harper et al 2005). 
Pharmacy services were generally very highly rated by women. There 
were some concerns about confidentiality and privacy among a 
substantial minority of users, particularly among younger women 
(Anderson et al 2006).  In general, the way in which services are 
configured affects their use, with women preferring services that 
give them privacy whilst treating them in a sympathetic and non-
judgmental manner.  It is worth noting that many of the studies 
were conducted prior to the increase in availability of consultation 
areas in pharmacies. Some concerns were also reported about 
the appropriateness of additional and unsolicited information 
and advice from pharmacists about future contraceptive use and 
sexually transmitted infections (STIs). 
sexually TransmiTTed infecTions
Four papers were reviewed, covering four studies. 
Chlamydia screening and other STI prevention roles appear 
promising – but privacy & confidentiality again are an issue.  In 
some developing countries, pharmacies already play a greater role 
in STI detection and treatment.
subsTance misuse
Eight papers were reviewed, covering eight studies. 
Ongoing pharmacy-based schemes such as needle-exchange and 
supervised methadone use appear to be reasonably well-accepted 
by clients, pharmacists and the public (with the exception that 
the public might prefer methadone supervision to be undertaken 
in private – i.e. not in the public area of the pharmacy).  There is 
potential for STI / HIV prevention advice to be given by pharmacists 
to drug service users.
osTeoporosis screening / prevenTion
Eight studies were reviewed, six of which provided community 
pharmacy-based osteoporosis screening, one a risk management 
service for patients taking long term oral corticosteroids and one a 
falls prevention service. 
overview
n  Community pharmacy based services for osteoporosis risk 
assessment were well received and identified women at different 
levels of risk.
n  Not all studies conducted follow up after the assessment and 
those that did found that preventive treatments had been initiated 
and that women reported having made lifestyle changes.
One study tested the feasibility of referral for screening by local 
family doctors using a list of criteria to target women who might 
be at risk (MacLaughlin et al 2005). The service was well received 
by women in all of the studies. Where follow up was conducted a 
substantial proportion of women had new prescriptions for relevant 
medicines, and substantial percentages of women reported having 
made lifestyle changes (MacLaughlin et al 2005; Summers et al 
2005; Naunton et al 2006).
A small RCT of a community pharmacy service tested the effect 
of pharmacist led risk management activities in patients taking 
long term oral corticosteroids (McDonough et al 2005). Intervention 
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pharmacies provided an educational pamphlet on osteoporosis 
prevention and reviewed patients’ medication while controls 
provided usual care. 96 patients participated and those in the 
intervention group were significantly more likely to be taking calcium 
supplements after 9-months. 
immunisaTion
Two studies (1 UK, 1 US) were reviewed, one of which was a service 
provision study. The UK pharmacy-based immunisation service (for 
influenza in particular) seems to have been reasonably well-accepted 
by patients, physicians and pharmacists (Hind et al 2004).
discussion
effecTiveness
Further evidence of the effectiveness of community pharmacy based 
services was identified for smoking cessation, hypertension, lipid 
management and diabetes.
Although overall there appear to be positive outcomes associated with 
pharmacy-based CHD management services, the studies conducted do 
not so far provide sufficient evidence to make a clear assessment. Most 
studies have only measured outcomes in the short term so the extent to 
which changes are sustained cannot be quantified. The exception is the 
Scrip Plus study where lower lipid levels were sustained one year after 
the end of the intervention period.
Currently the evidence for weight management might best be summed 
up as ‘promising and in need of further study.’ In the meantime, there 
are opportunities to collect data on effectiveness and it is encouraging 
to note that a government-funded Australian study will evaluate a 
community pharmacy weight-management service which itself is based 
on a critical review of the literature and the development of an evidence-
based service model (Rieck et al 2006).
QualiTy
Two service quality frameworks for smoking cessation were 
identified. No other studies assessed service quality.
cosTs and cosT-effecTiveness
We identified two robust cost effectiveness analyses of a diabetes 
management service and a comparison of two methods of diabetes 
screening.
Compared with previous reviews, studies were more likely to target 
specific groups of people for both screening and intervention, which 
is likely to increase cost-effectiveness.
There was no obvious theoretical basis for the ‘dose’ of pharmacist 
input used in the studies we reviewed. Monthly face-to-face 
consultations were common and there was no discussion in the 
papers about whether there might be a dose response curve which 
could help to identify optimal input. Some recent studies have 
used telephone follow ups as an alternative option to face-to-face 
consultations. One trial also included the possibility of follow up 
using electronic communication but this was not used.
skill mix
Only two studies included or discussed the contribution of pharmacy 
staff other than the pharmacist. One of these studies involved 
technicians in one pharmacy identifying people to receive brief 
advice on smoking. This was successful in doubling the numbers 
identified and recording their smoking status compared to the 
pharmacy which did not involve their technicians.
fuTure research
The dearth of UK studies in many key areas of the review is a 
matter for concern, with the exceptions of emergency hormonal 
contraception and substance misuse. In contrast, Canada has 
generated a substantial body of community pharmacy based 
research since our 2004 update and Australia has continued to 
expand its existing substantial evidence base.
In Australia a strategic long term programme of pharmacy 
practice research has produced a substantial evidence base to 
underpin proposed new community pharmacy services funded by 
the government. The key was collaborative working between the 
Australian government, the contract negotiators (The Pharmacy 
Guild of Australia), Schools of Pharmacy and the professional body. 
The Community Pharmacy Agreement Research and Development 
Program3 helped to establish Australia as an international leader 
in evidence based community pharmacy services. Research and 
development was one of the priorities identified in the Fourth 
Agreement between the government and The Pharmacy Guild of 
Australia (2005-10). Funding of up to $19 million (8.9 million GBP) 
has been allocated for the Research and Development Program 
to identify research and development priority areas in community 
pharmacy service provision and then to fund projects with the 
greatest potential to deliver services with positive health outcomes 
for consumers and economic impacts for the health system. An 
example from research the programme is the research on diabetes 
that led implementation of the pilot Diabetes Medication Assistance 
Service (DMAS)4  from 2007.Since September 2007, eligible patients 
with type 2 diabetes are able to schedule in-pharmacy appointments 
(with pharmacists in participating pharmacies) to receive assistance 
3http://www.guild.org.au/ (accessed 11/3/08).
4http://www.guild.org.au/uploadedfiles/Research_and_Development_Grants_Program/News_and_Events/RDmarketingbooklet.pdf (accessed 11/3/08).
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in managing their diabetes medicines, using a glucometer and 
self-monitoring their blood glucose. Pharmacists are also involved 
in the patient’s lifestyle management by providing regular blood 
pressure and weight measurements, as well as general health and 
lifestyle advice. To participate in the pilot programme, pharmacists 
must be credentialed against a competency based training course. 
Pharmacies must also have a private area within the pharmacy to 
allow for confidential sit-down consultations with the patient. 
If pharmacy-based studies are to have credibility with the wider 
public health community, it is important that they use key outcome 
measures that are recognised and accepted in relation to the 
particular health issue/s. For example, smoking cessation studies 
should be validated (e.g. by carbon monoxide or cotinine) wherever 
possible. This factor should be included in any quality assessment 
framework of smoking cessation services together with some 
assessment of behavioural support being given with medicines.
conclusions
The review found a substantial number of studies and their findings 
have strengthened the evidence base of effectiveness for community 
pharmacy based services in smoking cessation, CHD management 
and prevention, diabetes screening and management, hypertension 
– although most of the studies were conducted abroad in settings 
that might vary from those in the UK and therefore further research 
is required within the UK. Some evidence of effectiveness was found 
relating to osteoporosis risk assessment and weight management. 
These areas remain promising and should also be tested in pilot 
studies and further research. 
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